Company news

Ligand Pharmaceuticals Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

November 6, 2024

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

October 31, 2024

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

October 22, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

October 16, 2024

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

September 5, 2024

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

August 19, 2024

Ligand Reports Second Quarter 2024 Financial Results

August 5, 2024

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

July 22, 2024

Ligand to Acquire APEIRON Biologics AG for $100 Million

July 7, 2024

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

June 26, 2024

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

June 17, 2024

Ligand to Participate in Upcoming Investor Conferences

May 22, 2024

Ligand Reports First Quarter 2024 Financial Results

May 6, 2024

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

May 6, 2024

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

April 22, 2024

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

April 7, 2024

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

April 2, 2024

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

March 4, 2024

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 3, 2024

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

February 21, 2024

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

February 15, 2024

Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

February 12, 2024

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

January 4, 2024

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

December 11, 2023

Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City

December 5, 2023

Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications

November 30, 2023

Ligand Reports Third Quarter 2023 Financial Results

November 7, 2023

Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million

October 31, 2023

Ligand To Report Third Quarter 2023 Financial Results On November 8

October 24, 2023

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

October 17, 2023

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

September 26, 2023

Ligand Appoints Martine Zimmermann to its Board of Directors

September 25, 2023

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

September 21, 2023

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

September 17, 2023

Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

August 31, 2023

Ligand Reports Second Quarter 2023 Financial Results

August 7, 2023

Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

July 26, 2023

Ligand To Report Second Quarter 2023 Financial Results On August 8

July 24, 2023

Ligand Offers $15 Million to Acquire Assets of Novan, Inc.

July 16, 2023

Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

May 15, 2023

Ligand Reports First Quarter 2023 Financial Results

May 3, 2023

Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

April 23, 2023

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

February 21, 2023

Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

February 16, 2023

Ligand to Report Fourth Quarter Financial Results on February 22

February 5, 2023

Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

January 5, 2023

Ligand Provides Highlights from its Investor and Analyst Day Event

December 12, 2022

Ligand Pharmaceuticals Names Director Todd C. Davis as CEO

December 4, 2022

Ligand to Hold Investor and Analyst Day on December 13

November 15, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 44 decks. Every deck is listed under its year.